Solventum: Q4 EPS Beats, Cash Flow Dips
Diversified healthcare company Solventum (SOLV -0.71%) reported fourth-quarter 2024 earnings on Thursday, Feb. 27, that topped analysts' consensus estimates. Adjusted EPS for the quarter came in at $1.41 against an anticipated $1.31 and revenue of $2.074 billion exceeded the expected $2.050 billion.
Solventum Corporation (SOLV) Q4 2024 Earnings Call Transcript
Solventum Corporation (NYSE:SOLV ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Amy Wakeham - Senior Vice President of Investor Relations and External Finance Communications Bryan Hanson - Chief Executive Officer Wayde McMillan - Chief Financial Officer Conference Call Participants Jason Bednar - Piper Sandler & Co. Patrick Wood - Morgan Stanley David Roman - Goldman Sachs Group, Inc. Travis Steed - Bank of America Vikramjeet Chopra - Wells Fargo Securities Frederick Wise - Stifel, Nicolaus & Company, Inc. Operator Good afternoon. My name is Ellie, and I will be your conference call operator today.
Solventum forecasts annual profit above estimates on strong surgical product sales
3M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.
Nelson Peltz's Trian to push Solventum to further simplify business, WSJ reports
Activist investor Nelson Peltz's Trian Fund Management plans to push Solventum for further business separations following the company's $4.1 billion filtration unit sale, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Solventum In The Early Stages Of A Multiyear Turnaround Effort
Solventum In The Early Stages Of A Multiyear Turnaround Effort
Thermo Fisher buys Solventum's purification and filtration business for $4.1 billion
Contract drug manufacturer Thermo Fisher Scientific said on Tuesday it will buy Solventum's purification and filtration business for about $4.1 billion.
Billionaire Nelson Peltz Keeps Buying These 2 Stocks Hand Over Fist
Activist investor Nelson Peltz loves change. Seeking out undervalued and underperforming stocks, the billionaire often takes sizable positions in companies in a bid to unlock shareholder value via improvements in board representation, strategic overhauls, and operational efficiencies.
Peltz's Trian Fund says 3M's Solventum spin-off not living up to potential
Nelson Peltz's Trian Fund Management said in a letter to shareholders on Wednesday that medical device maker Solventum's separation from 3M has not been living up to its potential.
SOLV Stock Falls Despite Launch of Clarity Precision Grip Attachments
Solventum's Clarity precision grip attachments enhance treatment outcomes for orthodontic patients, reducing the risk of misplaced and malformed attachments.
Solventum Corporation (SOLV) Q3 2024 Earnings Call Transcript
Solventum Corporation (NYSE:SOLV ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Kevin Moran - SVP, IR Bryan Hanson - CEO Wayde McMillan - CFO Conference Call Participants Travis Steed - Bank of America Patrick Wood - Morgan Stanley Vik Chopra - Wells Fargo David Roman - Goldman Sachs Rick Wise - Stifel Ryan Zimmerman - BTIG Jason Bednar - Piper Sandler Chris Senyek - Wolfe Research Operator Good afternoon. My name is Amy, and I will be your conference operator for today.
SOLV Stock Gains as Q3 Earnings & Sales Beat Estimates, '24 View Up
Solventum's top line reflects the favorable impact of pricing normalization. Organic growth is primarily driven by rising demand for MedSurg products.
Solventum raises annual profit forecast on strong surgical product sales
3M spin-off Solventum raised its annual profit forecast on Thursday, betting on strong sales of its wound care and surgical sterilization products.
